Comparing the survival outcomes between the hypomethylating agents (HMAs) in SEER- Medicare database.
Phase of Trial: Phase IV
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Azacitidine (Primary) ; Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 29 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.